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early onset AD (EOAD)—control cohort, and examined 
the effect on transcript level with comprehensive third-
generation long-read sequencing. We characterized the 
ABCA7 coding sequence with next-generation sequencing 
in 928 EOAD patients and 980 matched control individu-
als. With MetaSKAT rare variant association analysis, we 
observed a fivefold enrichment (p = 0.0004) of PTC muta-
tions in EOAD patients (3%) versus controls (0.6%). Ten 
novel PTC mutations were only observed in patients, and 
PTC mutation carriers in general had an increased famil-
ial AD load. In addition, we observed nominal risk reduc-
ing trends for three common coding variants. Seven PTC 
mutations were further analyzed using targeted long-read 
cDNA sequencing on an Oxford Nanopore MinION plat-
form. PTC-containing transcripts for each investigated PTC 
mutation were observed at varying proportion (5–41% of 
Abstract Premature termination codon (PTC) mutations 
in the ATP-Binding Cassette, Sub-Family A, Member 7 
gene (ABCA7) have recently been identified as intermedi-
ate-to-high penetrant risk factor for late-onset Alzheimer’s 
disease (LOAD). High variability, however, is observed 
in downstream ABCA7 mRNA and protein expression, 
disease penetrance, and onset age, indicative of unknown 
modifying factors. Here, we investigated the prevalence 
and disease penetrance of ABCA7 PTC mutations in a large 
European Early Onset Dementia (EU EOD) consortium side 
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the total read count), implying incomplete nonsense-medi-
ated mRNA decay (NMD). Furthermore, we distinguished 
and phased several previously unknown alternative splic-
ing events (up to 30% of transcripts). In conjunction with 
PTC mutations, several of these novel ABCA7 isoforms 
have the potential to rescue deleterious PTC effects. In con-
clusion, ABCA7 PTC mutations play a substantial role in 
EOAD, warranting genetic screening of ABCA7 in geneti-
cally unexplained patients. Long-read cDNA sequencing 
revealed both varying degrees of NMD and transcript-mod-
ifying events, which may influence ABCA7 dosage, disease 
severity, and may create opportunities for therapeutic inter-
ventions in AD.
Keywords Early Onset Alzheimer’s disease · ATP-Binding 
Cassette · Sub-Family A · Member 7 (ABCA7) · Third-
generation long-read sequencing · RNA sequencing · Loss-
of-function · Modifier
Introduction
Alzheimer’s disease (AD, MIM: 104300) is the most 
common form of dementia. More than 20 genomic loci 
have been identified to contribute to AD risk [17, 18, 26, 
27, 37, 46]. Among those, the gene encoding ATP-Bind-
ing Cassette, Sub-Family A, Member 7 (ABCA7, MIM: 
605414) is of particular interest, because both common 
variants and rare variants are reported to affect AD risk 
[11, 13, 16, 27, 41, 44, 47, 49]. ABCA7 plays a role in 
lipid metabolism [20, 32, 43, 48] and microglial phago-
cytosis [15, 21, 31], and was linked to altered amyloid β 
(Aβ) processing [23, 43, 45], the predominant hypothesis 
on AD pathogenesis.
Deleterious premature termination codon (PTC) muta-
tions (nonsense, frameshift, and splice site mutations) 
in ABCA7 are observed at varying disease penetrance, 
with a 1.5–4× increased frequency in AD patients across 
populations [11, 16, 47, 49]. PTC mutation carriers 
appear more frequent among AD patients with a positive 
family history, though a wide range of disease onset age 
is observed [7, 11]. Two pedigrees have been reported 
in which a PTC mutation in ABCA7 (p.Arg578fs 
and p.Glu709fs) co-segregates with disease [10, 11]. 
Although the mode-of-action of ABCA7 PTC mutations 
in AD pathogenesis is unknown, a plausible mechanism 
is loss-of-function (LOF) due to nonsense-mediated 
mRNA decay (NMD). This is in line with mouse Abca7 
knockout experiments leading to increased Aβ brain lev-
els [15, 23, 43]. Single-epitope quantification of human 
brain mRNA and protein levels of ABCA7 in PTC muta-
tion carriers, however, is conflicting. High variability is 
observed between individuals in general and between 
PTC mutation carriers [1, 11]. Furthermore, mRNA and 
protein levels do not seem to correlate [1], necessitat-
ing analysis of ABCA7 expression in a broader context. 
In addition to PTC mutations, rare predicted deleteri-
ous missense mutations and some common missense 
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variants were, respectively, linked to risk increasing [16] 
and protective effects [11, 44], though requiring further 
confirmation.
The observation that ABCA7 PTC mutations exert a 
relatively strong effect on individual risk and familial 
occurrence of AD warrants further exploration of their 
potential in individualized genetic diagnosis and risk 
prediction [12]. To address the current complexity on a 
clinical and molecular level, we examined the prevalence 
and characteristics of ABCA7 coding mutations in a large 
European cohort of early onset AD patients (EOAD, 
onset age ≤65), a subgroup of AD patients that would 
strongly benefit from improved diagnosis, and genetic 
counseling. For a subset of PTC mutations, we performed 
targeted transcript analysis with third-generation (long-
read) sequencing to gain further insight in the mode-of-




The EOAD patients and control individuals were 
recruited within the European Early Onset Demen-
tia (EU EOD) consortium. Details about recruitment, 
in- and exclusion criteria, and demographic and patient 
characteristics were previously described [51]. In sum-
mary, patients [n = 928, 60.2% (558/927) female, 51.2% 
(391/763) APOE ε4+ (MIM: 107741)] were diagnosed 
according to NINCDS-ADRDA [34] and/or NIA-AA 
[19, 35] diagnostic criteria, and had a mean onset age 
of 57.4 ± 5.6 years (30–65). In 47.7% (274/575) of 
patients, a positive familial history for dementia was 
reported. Patients were ascertained in neurological cent-
ers with an expertise in memory disorders, and origi-
nated from Spain (n = 403), Italy (n = 159), Sweden 
(n = 160), Germany (n = 83), Portugal (n = 66), Greece 
(n = 52), and the Czech Republic (n = 5) (Table S1). 
Seventeen EOAD patients carried a known pathogenic 
mutation in PSEN1, PSEN2, or APP (MIM: 104311, 
600759, and 104760). Control individuals (n = 980, 
64.9% (607/936) female) had a mean inclusion age of 
63.9 ± 7.7 years (34-89), and were recruited in Spain 
(n = 223), Italy (n = 304), Sweden (n = 295), Portu-
gal (n = 120), Greece (n = 35), and the Czech Republic 
(n = 3). The study was approved by the respective ethics 
committees, and all participants and/or their legal guard-
ian provided written informed consent before inclusion.
ABCA7 sequencing
Genomic DNA (gDNA) was amplified with Illustra 
GenomiPhi v2 (Thermo Fisher, Waltham, MA, USA). 
Enrichment of 43 of the 47 canonical ABCA7 (RefSeq 
NM_019112.3) exons and splice sites was based on a cus-
tom multiplex PCR assay (primer sequences available upon 
request) generated with mpcr software (Multiplicom, Niel, 
Belgium). Regions of interest were amplified using flank-
ing primers with universal adapter sequences [5′-TCGTC 
GGCAGCGTCAGATGTGTATAAGAGACAG-(sequence-
specific forward primer) and 5′-GTCTCGTGGGCTC 
GGAGATGTGTATAAGAGACAG-(sequence-specific 
reverse primer)]. Amplicons were PCR barcoded with Nex-
tera XT sequences (Illumina, USA) targeting previously 
incorporated adapters. Samples were 2 × 300 bp paired-
end sequenced with MiSeq Reagent Kit v3 (Illumina, San 
Diego, CA, USA). Adapter clipping of demultiplexed 
FASTQ output was performed with fastq-mcf [3], aligned 
with Burrows-Wheeler Aligner MEMv0.7.5a [30] and vari-
ants were called with GATKv2.4 UnifiedGenotyper and 
GATKv3.5 HaplotypeCaller. Variants were annotated with 
GenomeComb [42] and SnpEff [9].
For four exons (12, 17, 19, and 23), no compatible prim-
ers were found. Exons 12, 17, and 19 were analyzed with 
Sanger sequencing: exons were PCR amplified, subse-
quently dideoxy-terminated with BigDye termination cycle 
sequencing kit v3.1 (Thermo Fisher), and sequenced with 
ABI3730 DNA Analyzer (Thermo Fisher). Sanger sequences 
were analyzed using Seqman (DNAstar, Madison, WI, USA) 
and NovoSNP software [52]. Exon 23 (73 bp + 4 bp splice 
sites) was not duly screened. Of note, this exon contains no 
known PTC mutations [Exome Aggregation Consortium 
(ExAC) (accessed April 2017)]. In addition, gaps are present 
(less than 50% of individuals sequenced at 20× coverage) 
in exon 9 (29 bp), 16 (23 bp), 18 (4 bp), and 21 (87 bp), as 
depicted in Fig. 1, mainly due to repetitive regions flanking 
ABCA7 exons, limiting efficient PCR primer design.
The sequencing read-depth statistics for all coding and 
splice sites regions are represented in Fig. 1 based on Rsam-
tools [36] and Circos visualization [25]. All PTC variants 
and c.5570+5G>C were validated on gDNA with Sanger 
sequencing as described above. In addition, we validated 
rare [minor allele frequency (MAF) <0.01%] missense vari-
ants with at least 20× read depth, a less than threefold dif-
ference between reference and alternative allele counts for 
heterozygous variants, and a Phred-scaled CADD score [24] 
above 20, corresponding to the 1% most deleterious variants 
in the human genome. This cutoff was chosen given the rel-
atively high mutational tolerance of ABCA7 and incomplete 
disease penetrance for very deleterious PTC mutations.
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Association analysis
Rare variant (MAF < 0.01) association meta-analysis by 
ethnicity was performed separately for PTC and predicted 
deleterious missense mutations using heterogeneous 
genetic effect SKAT-O statistics within the MetaSKAT 
framework [29]. APOE dosage (number of ε4 alleles) 
was tested as a covariate. Summary odds ratios  (ORMH) 
were calculated with a Cochran–Mantel–Haenszel test in 
PLINK [40], stratified by country of origin, on individu-
als without missing genotyping information.
For common variants (MAF ≥ 0.01), a fixed-effects 
(Cochran–Mantel–Haenszel) meta-analysis was used to 
calculate single variant allelic association. We evaluated 
all SNPs located within the CDS and 15 bp exon flank-
ing regions passing Hardy–Weinberg equilibrium quality 
control (p > 0.001). Odds ratios are reported for the minor 
allele with 95% confidence intervals. Pairwise linkage dise-
quilibrium (LD) was calculated in PLINK [40]. To account 
Fig. 1  ABCA7 mutation screening in EOAD. From the outside to the 
inside: HGVS nomenclature is denoted for known (black) and novel 
(red) PTC mutations, suggestively associated protective common 
variants (green), intron retaining variant c.5570+5G>C (orange), and 
predicted deleterious missense variants (gray). The second rim cor-
responds to the percentage of included individuals covered at more 
than 20× on the corresponding exonic position (0–50% in red and 
50–100% in green). Exons highlighted in blue were screened with 
Sanger sequencing. The third layer consists of the UTR (narrow) and 
CDS (broad) architecture of ABCA7 (NM_019112.3). Next, the corre-
sponding predicted protein domains (UniProtKB entry: Q8IZY2) are 
shown (transmembrane domains in green, extracellular parts in blue 
and red corresponds to ABC domains). In the center, the number of 
carriers per PTC (filled bars) and deleterious missense (open bars) 
variant are shown. Patients are represented in red, while control indi-
viduals are shown in blue. Linked variants (red, green, and gray line) 
segregated on the same haplotype
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for LD between variants, multiple testing thresholds were 
based on spectral decomposition [38], leading to a study-
wide multiple testing p value cutoff of 0.0033. Carriers of 
a known pathogenic mutation in APP, PSEN1, or PSEN2 
were excluded from association analyses.
Transcript analysis of PTC mutation carriers
Fresh frozen brain was available for patient EOD-P1 
(c.67-1G > A mutation). RNA was extracted from anterior 
cingulate cortex tissue with Ambion RiboPure™ kit (Life 
Technologies, Carlsbad, CA, USA). Reagent volumes 
were adapted to support 25 mg of input brain material. In 
addition, RNA from blood was extracted with Tempus™ 
blood RNA tube (Thermo Fisher) for carriers EOD-P7 
(p.Met370fs) and EOD-P19 (c.3577+1G>C). For a sub-
set of ABCA7 PTC mutations, EBV-transformed lympho-
cytes (p.Glu709fs, p.Trp1336*, and c.5570+5G>C) or 
fresh frozen brain tissue (p.Leu1403fs) from AD patients 
was available through the BELNEU consortium [11]. 
RNA was extracted with Ambion RiboPure™ kit (Life 
Technologies). All RNA was treated with Ambion TUR-
BODNase kit (Life Technologies) to degrade potential 
gDNA contamination. First-strand cDNA was synthesized 
with  SuperScript®III First-Strand Synthesis System (Life 
Technologies).
We performed cDNA sequencing on a MinION platform 
(Oxford Nanopore Technologies, Oxford, UK). Exonic 
primers were designed with Primer3Plus to generate ampli-
cons containing exons of interest, flanked by at least one 
splicing event on each side (Table S2). All PCR amplifi-
cations were performed with 35 cycles to have sufficient 
amplification of the lowly expressed ABCA7 in all tissues. 
Titanium Taq (Clontech Laboratories, Mountain View, CA, 
USA) or Platinum Taq (Thermo Fisher) enzymes were 
used with or without supplementation of betain, depend-
ing on the GC content of the amplicon. In case of overlap-
ping PCR amplicons, a 5′ barcoding adapter sequence was 
added to the primers and amplicons were barcoded with 
the PCR 96 barcoding genomic DNA (R9) kit (Oxford 
Nanopore Technologies) using 15 amplification cycles on 
a 1/125 diluted template. DNA was purified with Agen-
court AMPure XP SPRI beads (Beckman Coulter, Brea, 
CA, USA) and concentrations were measured with Qubit 
(Thermo Fisher). Amplicons were then pooled equimolar 
to a total quantity of 0.2 pmol. The resulting PCR library 
was then further prepared according to the manufacturer’s 
protocol. Briefly, DNA was treated with NEBNext Ultra 
II End Repair/dA-Tailing Module (New England Bio-
Labs, Ipswich, MA, USA). The product was then purified 
with AMPure XP beads, after which the ONT sequencing 
adapter and hairpin were ligated with the NEB Blunt/TA 
Ligase Master Mix (New England BioLabs). Next, biotin 
containing hairpin tethers were added and washed MyOne 
Streptavidin C1 Dynabeads (Thermo Fisher) were used for 
pull-down. Finally, the sequencing library was eluted from 
the beads and supplemented with Running Buffer with 
Fuel Mix. SQK-MAP006/NSK007 chemistry and FLO-
MAP103/MIN104 flow cells were used for sequencing. 
Base calling was done with the 2D plus barcoding proto-
col (Metrichor, Oxford, UK) after which FASTQ sequences 
were extracted with poretools v0.6.0 [33] according to 
the “best” protocol. Sequencing reads were aligned to the 
human genome (hg19) with GMAP v2016-06-30 [53] to 
account for splicing events. Wild-type (WT), nonsense, and 
rescue alleles were quantified with Rsamtools v1.26.0 for 
aligned sequences [36], and with GMAP splicesites out-
put for splicing events. The PTC expression fraction was 
calculated as  (expressionNonsense/expressionNonsense+WT); 
0% corresponds to complete degradation of PTC bearing 
transcripts and 50% to equal observance of PTC and WT 
transcripts. Results were validated with Sanger sequencing 
of cDNA amplicons as described above and compared with 
RNA sequencing (RNAseq) data from a Belgian unrelated 
AD-control transcriptome study [51]. Briefly, total RNA 
was isolated from Epstein–Barr virus immortalized lymph-
oblasts derived from whole blood lymphocytes. RNA iso-
lation of lymphoblast cells was performed with the RNe-
asy mini kit (Qiagen Inc., Valencia, CA, USA) according 
to the manufacturer’s protocol. Sequence libraries were 
constructed using the Truseq stranded mRNA Library Prep 
Kit v2 (Illumina) using 1 mg total RNA for each sample. 
Sequencing of prepared libraries was performed using an 
Illumina HiSeq 2000 sequencer generating an average of 
72 × 106 ± 6 × 106 paired-end sequence reads/sample. 
Subsequent data processing consisted out of removal of 
read adapters and trimming of read ends with Trimmomatic 
[6]. Reads were then aligned to hg19 using the Bowtie 
short read aligner integrated in Tophat2 [22].
Results
PTC mutations
Sequencing of the ABCA7 CDS in 928 EOAD patients 
and 980 control individuals revealed 17 different PTC 
mutations (six frameshift indels, six nonsense muta-
tions, and five PTC-introducing splice site muta-
tions) (Table 1), which were more frequent in EOAD 
patients (3.02%; n = 28) than controls (0.61%; n = 6) [p 
value = 0.0004,  ORMH = 5.01 (95% CI = 1.59–15.72)]. 
This association remained significant after correction for 
APOE (p = 0.001). Most PTC mutations (n = 10) were 
not reported before and—together with c.67-1G > A, 
c.3577 + 1G > C, and p.Arg1489*—were absent from 
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control individuals (Fig. 1; Table S3). Patient EOD-P5 
carried two PTC mutations (p.Trp69*and c.579+1G>T) 
segregating on the same haplotype (Figure S1). Two previ-
ously reported variants (p.Trp1336*, c.4416+2T>G) were 
only observed in control individuals. The two most fre-
quent PTC mutations (p.Glu709fs and p.Leu1403fs) were 
observed more in patients than control individuals (Fig. 1; 
Table 1). All carriers of p.Glu709fs and p.Leu1403fs 
shared the same respective haplotype (Table S4). Car-
riers of less frequent multiple occurring variants (c.67-
1G>A, p.Thr849fs, c.4416+2T>G, and p.Arg1489) were 
geographically confined (respectively, originating from 
Spain, Portugal, Italy, and the Iberian Peninsula), though 
no familial relatedness was known (Table S3).
Patients (n = 28, 75.0% female, 54.2% (13/24) APOE 
ε4 +) carrying PTC mutations had a mean onset age of 
56.7 ± 5.5 years (42-65, upper limit determined by inclu-
sion criteria for EOAD), and a mean disease duration 
of 8.6 ± 1.8 years (Table S3). In comparison, carriers of 
established pathogenic mutations in PSEN1 (n = 12), 
PSEN2 (n = 3), or APP (n = 2) had a lower mean onset age 
of, respectively, 46.0 ± 9.0, 53.0 ± 5.1, or 49.5 ± 1.5 years 
Table 1  ABCA7 PTC mutations
An overview of all premature termination codon (PTC) inducing mutations observed in this study. Genomic coordinates are based on hg19. 
HGVS = mutation nomenclature according to the Human Genome Variation Society. dbSNP notations refer to Reference SNP IDs (rs) from 
dbSNP build 142. MAF minor allele frequency. The previous reports of the mutation in discovery populations of Cuyvers et al. (1), Steinberg 
et al. (2), Le Guennec et al. (3), or Nuytemans et al. (4) are denoted. Abundance of the PTC transcript is shown based on MinION cDNA 
sequencing (Figures S3–S5, S8, and S10). PTC expression fraction corresponds to the abundancy of sequencing reads containing the PTC muta-
tion, in which case 0% is associated with complete degradation of PTC transcripts, and 50% with equal expression of PTC and WT alleles. 
Reading frame restorations are denoted when identified and correspond either to in-frame skipping of the exon harboring the mutation of inter-
est, or alternative splicing which restores the reading frame without introduction of a PTC. The same cDNA PCR amplicon was used to measure 
exon skipping events for p.Trp1336* and p.Leu1403fs; as a result, both exons could be quantified for two different individuals (range)
Genomic posi-
tion




















 chr19:1041508 c.67−1G>A – rs199517248 3 (0.16%) 0 (0%) 1, 3 5% –
 chr19:1041565 c.124_130dupGTTCGCC p.His44fs – 1 (0.05%) 0 (0%) Novel – –
 chr19:1041875 c.206G>A p.Trp69* – 1 (0.05%) 0 (0%) Novel – –
 chr19:1041972 c.302+1G>C – – 1 (0.05%) 0 (0%) Novel – –
 chr19:1042826 c.579+1G>T – – 1 (0.05%) 0 (0%) Novel – –
chr19:1044636 c.1109dupT p.Met370fs – 1 (0.06%) 0 (0%) Novel 21% Exon 
skipping 
(2%)
chr19:1047275 c.1968_1977delTGCGGCCTGC p.Cys659fs – 1 (0.07%) 0 (0%) Novel – –
chr19:1047507 c.2126_2132delAGCAGGG p.Glu709fs rs547447016 6 (0.36%) 2 (0.12%) 1, 2, 3, 4 41% Alternative 
splicing 
(10%)
chr19:1047518 c.2134G>T p.Glu712* – 1 (0.06%) 0 (0%) Novel – –
chr19:1047578 c.2194C>T p.Gln732* – 1 (0.06%) 0 (0%) Novel – –
chr19:1049426 c.2544delC p.Thr849fs – 2 (0.11%) 0 (0%) Novel – –
chr19:1054110 c.3577+1G>C – rs373195428 1 (0.05%) 0 (0%) 3 36% –
chr19:1055153 c.4008G>A p.Trp1336* – 0 (0%) 1 (0.05%) 3 27% Exon 
skipping 
(8–30%)
chr19:1055907 c.4208delT p.Leu1403fs rs538591288 5 (0.27%) 1 (0.06%) 1, 2, 3, 4 38% Exon 
skipping 
(3–4%)
chr19:1056208 c.4382G>A p.Trp1461* – 1 (0.05%) 0 (0%) Novel – –
chr19:1056244 c.4416+2T>G – rs113809142 0 (0%) 2 (0.10%) 2, 3, 4 – –
chr19:1056377 c.4465C>T p.Arg1489* – 3 (0.17%) 0 (0%) 3 – –
Splice affecting mutation
 chr19:1061892 c.5570 + 5G>C – rs200538373 6 (0.38%) 7 (0.38%) 1, 2, 3 30% –
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(35-63, p = 0.0002) (Figure S2). Patient EOD-P6.1 
(ABCA7 c.302 + 1G>C) also carried a pathogenic PSEN1 
mutation (p.His163Arg) and had the earliest onset age 
(42 years) of all ABCA7 PTC carriers. Two affected rela-
tives of EOD-P6.1 also carried PSEN1 p.His163Arg, but 
not ABCA7 c.302+1G>C, and had a slightly older onset 
age of 46 years.
A positive familial history for dementia was reported 
in 61.5% (16/26) of patient carriers. Of note, for patient 
EOD-P21.1 carrying p.Leu1403fs, DNA was available of 
two affected relatives with onset ages of 68 and 70 years, 
who both also carried the mutation. In addition, EOD-P7 
(p.Met370fs) and EOD-P20 (p.Leu1403fs) had a negative 
familial history for dementia, but both had a first-degree 
relative with Parkinson’s disease. Information on clinical 
presentation was available for 23 patients, of whom 82.6% 
(19/23) had a predominant amnestic presentation. In two 
patients, the onset of memory dysfunction was accom-
panied by language dysfunction. EOD-P6.1 (carrying 
PSEN1 p.His163Arg) had prominent behavioral symptoms 
(aggressiveness). Only one patient presented with a clear 
nonamnestic phenotype (logopenic progressive aphasia). 
Neuropathology was available for EOD-P1, confirming the 
clinical AD diagnosis (Fig. 2, Neuropathological descrip-
tion S1).
Transcript analysis of PTC mutations
We examined ABCA7 expression with MinION sequenc-
ing for three frameshift mutations (p.Met370fs, 
p.Glu709fs, and p.Leu1403fs), one nonsense 
(p.Trp1336*), one splice donor (c.3577 + 1G > C), and 
one splice acceptor mutation (c.67-1G>A). We observed 
varying degrees of PTC bearing transcripts in all cDNA 
libraries (Fig. 3; Table 1), indicative of incomplete 
NMD. The most N-terminal mutation (c.67−1G>A) had 
the highest NMD efficiency with only 5% of sequencing 
reads showing out-of-frame exon 3 skipping. All other 
mutations presented higher PTC abundancy (21–41%), 
approaching expression equal to the WT allele (50%). 
On top of apparent NMD escape, we observed alterna-
tive splicing events, absent from public databases (e.g., 
Ensembl, GENCODE, and UCSC genes), in mutated 
regions of interest. Some have the ability to restore 
reading frameshifts caused by PTC mutations (Fig. 3; 
Table 1). For three mutations (p.Met370fs, p.Trp1336*, 
and p.Leu1403fs), in-frame skipping of the respective 
PTC bearing exon [exon 11 (168 bp), exon 30 (255 bp), 
and exon 31 (33 bp)] was observed in patient carriers 
(Figures S3, S4, and S5). Overall, potential PTC res-
cue transcripts had a modest abundance (2–8%); how-
ever, in brain cDNA of one individual, we observed 
skipping of exon 30 in 30% of all sequencing reads, 
in this case unrelated to a PTC (Figure S5). These in-
frame exon skipping transcripts were validated with 
RNAseq, confirming their presence in individuals not 
carrying an ABCA7 mutation (Figure S6 and S7). Fur-
thermore, for p.Glu709fs (exon 16), we observed usage 
of a cryptic splice donor site (10%) in the same exon 
(Figure S8), which can negate the frameshift effect of 
p.Glu709fs. Validation of this splicing isoform with 
RNAseq is presented in Figure S9, along with confir-
mation of its presence in a physiological context. West-
ern blotting was performed on brain of c.67−1G>A 
and p.Leu1403fs (Method S1), confirming a reduc-
tion of expression by PTC mutations (Figure S11), as 
well as an overall variability in expression. One splice 
mutation (c.5570+5G>C)—3 bp downstream of the 
canonical splice donor site—was previously reported 
to cause out-of-frame intron retention [47]. Here, this 
Fig. 2  Neuropathological findings in patient EOD-P1. Abundant 
beta-A4 amyloid pathology in the form of diffuse and cored amyloid 
plaques (a) and amyloid angiopathy involving leptomeningeal vessels 
(b). Prominent phospho-tau pathology in the form of neurofibrillary 
tangles, dystrophic neurites, and neuropil threads (c). Scale bars: a, c 
50 μm, b 20 μm. An extended neuropathological description is avail-
able in Neuropathological description S1
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variant showed no association: we observed the minor 
C-allele in six EOAD patients (MAF = 0.38%), of 
which one was homozygous, and seven control indi-
viduals (MAF = 0.38%)  [ORMH = 1.28 (0.44–3.74), 
p value = 0.86; Table S5]. RNAseq and MinION 
sequencing confirmed out-of-frame partial intron 41 
retaining capability of c.5570+5G>C, but additional 
splicing events in the locus were observed as well 
(i.e., exon 41 skipping, and varying intron 41 retention 
lengths) (Figure S10).
Fig. 3  Schematic representation of PTC mutations and their effect on 
transcripts as well as corresponding potential rescue mechanisms. a 
The canonical ABCA7 transcript is shown from exon 1 (top) to exon 
47 (bottom). Exons in red harbor a PTC inducing mutation (HGVS 
notation in red) which was analyzed on transcript level. Observed 
transcripts generated through MinION cDNA sequencing of patient 
cDNA are shown in two panels: NMD escaping transcripts harbor-
ing PTC mutations (b) and potential rescued transcript through 
alternative splicing (c). PTC inducing mutations (vertical red line), 
transcribed regions (broad, numbered segments) and connecting non-
transcribed introns (horizontal lines), are shown. The transcript read-
ing frame is either in-frame (green) or out-frame (orange). The first 
induced PTC mutation is denoted with an asterisk. Downstream tran-
script which is not translated and results in truncated ABCA7 protein 
is shaded in gray. Exons completely in gray are skipped and alter-
native splicing is shown as caret-like connectors, or as transcribed 
fragments in the case of intron retention. Alternative splicing events 
can either be deleterious (pink), or may potentially rescue transcripts 
(blue). Raw sequencing data supporting alternative splicing are 
shown for two cases in (d) and (e): Overall, read depth per position 
is represented on top as a bar chart (gray for reference nucleotides, 
different colors for SNPs). Separate long sequencing reads are shown 
below (gray bars for aligned sequences, blue lines for connecting 
splicing events, and black lines for deletions), and the exonic layout 
of ABCA7 is depicted at the bottom (blue bars). d MinION cDNA 
sequencing of a patient carrying c.3577 + 1G > C confirms complete 
out of frame retention of intron 26. e MinION cDNA sequencing 
confirms that both exon 30 and 31 can be skipped in-frame and can, 
therefore, alter the effect of PTC mutations positioned in these exons 
(i.e., p.Trp1336* and p.Leu1403fs, respectively)
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Other coding variants
We identified 19 predicted deleterious missense muta-
tions (CADD score >20). There was no enrichment of 
predicted deleterious missense variants in patients (1.7%; 
n = 16) compared to controls (0.92%; n = 9; SKAT-O p 
value = 0.67) (Fig. 1; Table S6). Of note, p.Ala676Thr and 
p.Ser1723Leu segregated together in two controls and one 
patient; for which the patient, in addition, carried a third 
deleterious in-frame deletion (c.4922_4924delTCT). Clini-
cal characteristics of missense mutation carriers did not dif-
fer substantially from PTC mutation carriers [mean onset 
age 57.0 ± 5.5 years (range = 46–55); positive familial 
history in 60.0% (6/10)].
Twenty-two common coding variants (MAF > 1%), 
were assessed for association with EOAD. No vari-
ants passed study-wide multiple testing correction 
(p = 0.0033), but nominal significance was observed for 
three SNPs (Table S7). The strongest effect [OR = 0.60 
(95% CI = 0.42–0.87), p = 0.006] was observed for 
p.Gly215Ser (rs72973581, MAF = 4.1%), a missense 
SNP previously suggested to be protective [44]. For silent 
variant p.Asn1829Asn (rs78320196, MAF = 4.7%), 
we observed an OR of 0.65 (95% CI = 0.47–0.90; 
p value = 0.009). The potential protective effect of 
p.Asn1829Asn seems independent of p.Gly215Ser, given 
low pairwise LD (R2 = 0.001 and D′ = 0.596). The third 
variant (p.Glu188Gly, rs3764645, and MAF = 43.4%) 
also showed a suggestive protective effect (OR = 0.86 
95% CI = 0.75–0.99), p value = 0.030), which was previ-
ously reported in a Belgian cohort of AD [11]. We further 
observed that p.Glu188Gly and p.Gly215Ser were in strong 
LD (D′ = 0.961).
Discussion
Predicted LOF mutations in ABCA7 were recently put for-
ward as intermediate-to-high penetrant risk factors for AD. 
To evaluate their contribution to EOAD, we sequenced 
the ABCA7 coding DNA of 928 European EOAD patients 
and 980 ethnically matched healthy control individuals. 
We identified ten novel patient-specific PTC mutations 
(frameshift, nonsense, and canonical splice mutations), and 
confirmed seven previously reported mutations. ABCA7 
PTC mutations were five times more frequent among 
EOAD patients than controls, confirming an important con-
tribution of these mutations to AD. Transcript analysis of 
seven PTC mutations revealed varying degrees of loss-of-
transcript, suggesting that the mechanism through which 
these mutations affect AD risk needs further investigation. 
We observed no associations for predicted deleterious 
missense mutations, but detected a protective trend for 
three common variants.
ABCA7 PTC mutations were detected in approximately 
3% of the EOAD patients, which is comparable to the 
previous reports [11, 16]. In comparison, predicted patho-
genic PTC mutations in SORL1 (MIM: 602005)—another 
prominent AD risk gene—were observed in 0.6% of EOAD 
patients in the EU EOD consortium [51]. Furthermore, only 
an estimated 5–10% of EOAD can be explained by auto-
somal dominant mutations in APP (<1%), PSEN1 (6%), 
and PSEN2 (1%) [8]. Hence, due to relative high pene-
trance and occurrence, genetic screening for ABCA7 PTC 
mutations is warranted in genetically unexplained EOAD 
patients. In line with the previous reports, we observed a 
high familial load in patients carrying an ABCA7 PTC 
mutation—though lower than in established autosomal 
dominant mutation carriers. In one Italian AD family 
(EOD-P21), multiple affected relatives carried the ABCA7 
p.Leu1403fs mutation. Further elucidation of age-related 
penetrance and segregation patterns of individual ABCA7 
mutations—and possible modifiers thereof—will be imper-
ative for implementation of ABCA7 mutation screening in 
clinical practice and genetic counseling.
Based on the previous reports and the arbitrary posi-
tioning of AD associated PTC mutations across the gene 
(Fig. 1), haploinsufficiency—a reduction of dosage sensi-
tive functional ABCA7—is the most plausible pathogenic 
mechanism [11, 16, 47]. Additional expression differ-
ences—either dosage recovery or further ABCA7 deple-
tion—are, therefore, potential modifiers. We examined the 
effect of frameshifts, nonsense, splice donor, and splice 
acceptor variants on ABCA7 transcripts in patient bioma-
terials using “third-generation” long-read MinION cDNA 
sequencing. Even though this sequencing technology is still 
under development and currently produces a relatively high 
random base calling error rate, we show that the accuracy is 
sufficient to align reads and to identify splicing events. Fur-
thermore, given the high read depth attained in this targeted 
experiment (at least 1400×), reliable consensus sequences 
and variant calls could be formed.
Interestingly, we observed PTC transcripts for all muta-
tions under study, indicating NMD escape. The proportion 
of sequencing reads carrying a PTC varied across muta-
tions, up to 41% which is close to no NMD (50%). As a 
consequence of NMD escape, ABCA7 dosage may be 
modified, either via natural PTC read-through resulting in 
full length protein [5], or on the other hand through forma-
tion of truncated proteins which could exert dominant nega-
tive or wild-type functions. NMD escape also opens a win-
dow for pharmacological intervention. Several compounds 
are known to cause ribosomal read-through of PTCs, which 
could result in a functional protein and alleviate haploin-
sufficiency. Especially carriers of nonsense mutations may 
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benefit from such a treatment. Read-through compounds 
(e.g., PTC124) are currently tested in clinical trials for LOF 
diseases such as Duchenne muscular dystrophy (DMD, 
MIM: 310200) and cystic fibrosis (MIM: 219700) [5].
In contrast to standard RNAseq, MinION sequencing of 
long DNA fragments at high read depth provided insights 
in phasing of mutations and splicing events despite low 
ABCA7 expression [39]. As a result, we observed alterna-
tive splicing events unknown to public repositories. We 
identified cryptic splice site usage, often leading to a shift 
in reading frame, as well as exon skipping, both in- and 
out-of-frame. On one hand, these events can lower the 
ABCA7 cell reserve resulting in stronger dosage depletion 
when a PTC mutation is introduced. On the other hand, 
several splicing events have the potential to recover the 
effect of PTC causing mutations (e.g., reading frame rescue 
through usage of a cryptic splice site), or alter the amount 
of transcript carrying a PTC mutation (e.g., in-frame skip-
ping of an exon harboring a mutation). Interestingly, for 
all PTC mutations observed in controls with the exception 
of c.4416+2T>G for which no biomaterials were avail-
able, a potential rescue mechanism was present (Table 1). 
For some mutations, the rescue event appears relatively 
frequent, which may contribute to incomplete penetrance 
(e.g., p.Trp1336* has been reported in both patients and 
controls; we observed exon 30 skipping in up to 30% of 
reads). Stabilization of alternative isoforms (e.g., through 
oligonucleotides targeting pre-mRNA) is a potential phar-
macological target, which is already being evaluated for 
diseases as DMD and spinal muscular atrophy (MIM: 
253300) [14].
Further research into the functions, essential protein 
domains, expression, and different isoforms of ABCA7 
will have to substantiate to which extent dosage can mod-
ify the AD phenotype, and whether it can be remediated. 
It is likely that numerous factors contribute significantly to 
variation in ABCA7 expression (as evidenced by protein 
levels in hippocampus, Figure S11), including brain degen-
eration, inflammation, specific brain regions/cellular com-
position, disease duration, genetic etiology, and environ-
mental factors. The long-read cDNA sequencing approach 
used here shows that differences in ABCA7 transcript and 
protein expression data may also partly be explained by a 
myriad of NMD escaping alternatively spliced transcripts 
and (truncated) proteins. Taken together, this may explain 
discrepancies within and between the previous studies on 
ABCA7 expression [1, 2, 50]. In this study, ABCA7 tran-
scripts of PTC mutations were examined in different patient 
tissues (brain, blood, and lymphoblast), which may pre-
sent varying NMD efficiencies [54] and alternative splic-
ing [4]. Ideally, quantitative comparisons of ABCA7 dosage 
between carriers are performed on a larger series of muta-
tion carriers in a single tissue to more precisely determine 
the contribution of NMD efficiency and transcript rescue 
to variation in ABCA7 gene expression. In this study, we 
aimed at adequate coverage of lowly abundant ABCA7 tran-
scripts by sequencing mutation-specific amplicons, which, 
in addition, also prevents the formation of chimeric PCR 
molecules that might lead to phasing errors [28]. When cur-
rent limitations of long-range PCR are overcome, it will 
be of interest to expand the methods used here to obtain a 
detailed map of transcript events across full length ABCA7 
mRNA.
In addition to canonical PTC mutations, 
c.5570 + 5G > C is known to cause out-of-frame intron 
retention [47], which we confirm (Figure S10). While 
others have observed association with this variant [16, 
47], here, no enrichment was present  (ORMH = 1.28 95% 
CI = 0.44–3.74), p value = 0.86). Possibly, c.5570+G>C 
has a different protein reducing effect than canonical PTC 
mutations, since the degree of cryptic splice donor site ver-
sus canonical usage is unknown, and due to the relatively 
distal location of c.5570+5G>C in the protein. Further-
more, several interfering isoforms were present, suggest-
ing lower penetrance of this particular variant. A previous 
report also suggested the pathogenicity of predicted dam-
aging ABCA7 missense variants [16]. In this study, with a 
larger study population, however, we observed no obvious 
enrichment (p = 0.66). Furthermore, we observed two dele-
terious missense variants (p.Ala676Thr and p.Ser1723Leu) 
segregating on the same haplotype, which occurred in both 
patients and controls. We cannot exclude that our cohort 
lacked power to observe a likely smaller effect of missense 
mutations on disease risk, but at this point, it is premature 
to draw inferences based on deleteriousness predictions 
alone. If future studies reveal a risk increasing effect of (a 
subset of) ABCA7 missense variants, it may be worthwhile 
to elucidate the effect of these mutations on mRNA splic-
ing and vice versa.
Finally, three common coding variants (p.Gly215Ser, 
p.Glu188Gly, and p.Asn1829Asn) showed a trend towards 
decreased risk of EOAD, albeit not withstanding multiple 
testing. Of note, p.Gly215Ser was previously put forward 
as protective variant in ABCA7 [44], and for p.Glu188Gly 
and p.Asn1829Asn, a nominal protective association was 
also observed before [11, 44]. We show that p.Gly215Ser 
and p.Glu188Gly shared the same haplotype background 
(D′ = 0.961). In this study, we extend potential protect-
ing effects of p.Gly215Ser and p.Asn1829Asn towards 
EOAD, supporting the role of ABCA7 to mediate risk of 
(early onset) AD in both directions. Further research, how-
ever, is required to understand the downstream protective 
mechanisms.
In summary, with this targeted resequencing of ABCA7 
in a large European cohort of EOAD, we substanti-
ate the evidence that ABCA7 PTC mutations contribute 
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significantly to AD risk. We observed a fivefold enrich-
ment of ABCA7 PTC mutations in EOAD patients, and pro-
vided further evidence that these mutations may segregate 
with disease in pedigrees. This suggests that at least some 
ABCA7 mutations may have a high penetrance, providing 
new inroads for genetic subtyping and risk prediction. The 
observation of these ‘familial’ ABCA7 mutations in cog-
nitively healthy individuals, however, warrants cautious 
interpretation and further exploration of pathogenicity and 
modifying factors. An initial characterization of different 
PTC mutations at transcript level reveals substantial vari-
ability in NMD and alternative splicing, implying varying 
abundancy of ABCA7 in PTC mutation carriers. Further 
investigation is required into the degree of dosage reduc-
tion caused by a single mutation, the function and structure 
of ABCA7, and the presence of potential dominant negative 
effects, to contribute to a better estimation of phenotypical 
consequences and ways to remediate this.
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